Padsevonil clinical trials
Also written UCB0942.
How each study uses padsevonil is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2019 (7)
| Year | Studies |
|---|---|
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 7 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses padsevonil is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant EpilepsyCompletedPhase 2UCB Biopharma S.P.R.L.NCT03373383Written as PadsevonilHow we know
- A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant EpilepsyTerminatedPhase 3UCB Biopharma SRLNCT03739840Written as PadsevonilHow we know
- An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal EpilepsyTerminatedPhase 2UCB Biopharma SRLNCT02625090Written as UCB0942How we know
- Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant EpilepsyTerminatedPhase 2UCB Biopharma SRLNCT03370120Written as PadsevonilHow we know
- A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic FunctionTerminatedPhase 1UCB Biopharma S.P.R.L.NCT04136444Written as PadsevonilHow we know
- Study to Evaluate the Effect of Coadministered Erythromycin on the Pharmacokinetics and Safety of PadsevonilCompletedPhase 1UCB Biopharma S.P.R.L.NCT03480243Written as Padsevonil (UCB0942)How we know
- A Study to Test the Safety, and Tolerability of Padsevonil in Healthy Male Japanese Study ParticipantsCompletedPhase 1UCB Biopharma S.P.R.L.NCT04075409Written as PadsevonilHow we know
- A Study to Test the Safety and Tolerability of Single and Multiple Doses of Padsevonil in Adult and Elderly Study ParticipantsCompletedPhase 1UCB Biopharma S.P.R.L.NCT04013191Written as PadsevonilHow we know
- A Study to Test the Interaction of Padsevonil With Oral Contraceptives in Healthy Female ParticipantsTerminatedPhase 1UCB Biopharma SRLNCT04131517Written as PadsevonilHow we know
- A Study to Test the Cardiac Effects of Padsevonil in Healthy Study ParticipantsTerminatedPhase 1UCB Biopharma S.P.R.L.NCT04126343Written as PadsevonilHow we know
- A Study to Test the Pharmacodynamic, Pharmacokinetic, Safety, and Tolerability of Padsevonil in Healthy Study Participants Receiving Either Ethanol or CannabidiolTerminatedPhase 1UCB Biopharma S.P.R.L.NCT04039919Written as PadsevonilHow we know
- A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on PadsevonilCompletedPhase 1UCB Biopharma S.P.R.L.NCT03695094Written as PadsevonilHow we know
- A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal EpilepsyCompletedPhase 2UCB Biopharma S.P.R.L.NCT02495844Written as UCB0942How we know
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB0942 in Healthy Japanese and Caucasian SubjectsCompletedPhase 1UCB Biopharma S.P.R.L.NCT03168984Written as UCB0942How we know
Codes
What other systems call padsevonil · ClinicalTrials.gg INT001366
- MeSH (NLM) C000708857padsevonilConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 0R1HN52K0NPADSEVONILConfirmed FDA, NLM, Wikidata
- Wikidata Q27237119padsevonilConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166432PadsevonilOne source FDA
- DrugBank DB14977One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000708857 | padsevonil | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 0R1HN52K0N | PADSEVONIL | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27237119 | padsevonil | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166432 | Padsevonil | One source FDA |
| DrugBank | DB14977 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.